glp-1 receptor agonist type 1 diabetes randomized trial Glucagon-like peptide-1 agonists and risk of suicidality among patients with 2 diabetes: active comparator, new user cohort study Glucagon-like peptide-1 (GLP-1) receptor agonists
Description
Houston BT et al
It would be interesting to understand what actually maintains that state
Tirzepatide, a dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound), has demonstrated even greater weight loss in clinical trials
Improved tolerability could therefore become an important competitive advantage if these findings translate successfully into clinical studies
117: 23402350 [DOI] [PubMed] [Google Scholar] 163.Bose AK, Mocanu MM, Carr RD, et al
